Form 4: Director Renee Gala Receives RSU Grant at DexCom
Director Equity Grant Disclosure
Director Renee D. Gala was granted 5,605 restricted stock units as part of her equity compensation at DexCom, Inc.
Summary
- Director Renee D. Gala received a grant of 5,605 restricted stock units (RSUs) on May 28, 2026.
- The RSUs represent a contingent right to receive one share of DexCom, Inc. common stock per unit upon settlement.
- The grant is scheduled to vest on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting of Stockholders.
- Following this transaction, the reporting person holds a total of 12,486 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.
Positives
- The equity grant aligns the director's interests with those of shareholders through long-term stock ownership.
Negatives
- None identified; this is a standard equity compensation disclosure.
Risks
- The value of the granted RSUs is subject to market volatility and the future performance of DexCom, Inc. common stock.
Future Outlook
The RSUs are set to vest in approximately one year, contingent upon the director's continued service or the occurrence of the 2027 Annual Meeting.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to ensure alignment between board members and shareholders in the medical device and continuous glucose monitoring sector.
Comparison to Industry Standards
- The use of RSUs as a primary vehicle for director compensation is consistent with standard practices among S&P 500 and mid-cap healthcare technology companies.
- Vesting schedules tied to annual meetings are a common industry benchmark for board-level equity awards.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Filing of a Power of Attorney authorizing specific individuals to handle SEC filings on behalf of the director. | 06/11/2025 | Standard administrative procedure to ensure timely regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders; reflects standard board compensation practices.
Next Steps
- Vesting of the 5,605 RSUs on the earlier of May 28, 2027, or the 2027 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 06/11/2025 | Date of Power of Attorney execution. |
| 03/06/2025 | Grant date of previous RSU holdings. |
| 05/28/2026 | Date of the reported RSU grant transaction. |
| 06/01/2026 | Date of signature for the Form 4 filing. |
Keywords
DexCom, DXCM, Director, Equity Compensation, Restricted Stock Units, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.